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OBJECTIVE — To determine the effect of treatment with insulin aspart compared with NPH
insulin, together with metformin/placebo and rosiglitazone/placebo. The hypothesis was that
combined correction of major pathogenetic defects in type 2 diabetes would result in optimal
glycemic control.
RESEARCH DESIGN AND METHODS — This study was a 2-year investigator-driven
randomizedpartlyplacebo-controlledmulticentertrialin371patientswithtype2diabetesonat
least oral antiglycemic treatment. Patients were assigned to one of eight treatment groups in a
factorial design with insulin aspart at mealtimes versus NPH insulin once daily at bedtime,
metformin twice daily versus placebo, and rosiglitazone twice daily versus placebo. The main
outcome measurement was change in A1C.
RESULTS — A1C decreased more in patients treated with insulin aspart compared with NPH
(0.41  0.10%, P  0.001). Metformin decreased A1C compared with placebo (0.60 
0.10%, P  0.001), as did rosiglitazone (0.55  0.10%, P  0.001). Triple therapy (rosigli-
tazone, metformin, and any insulin) resulted in a greater reduction in A1C than rosiglitazone
plus insulin (0.50  0.14%, P  0.001) and metformin plus insulin (0.45  0.14%, P 
0.001).Aspartwasassociatedwithahigherincreaseinbodyweight(1.60.6kg,P0.01)and
higher incidence of mild daytime hypoglycemia (4.9  7.5 vs. 1.7  5.4 number/person/year,
P  0.001) compared with NPH.
CONCLUSIONS — Insulin treatment of postprandial hyperglycemia results in lower A1C
thantreatmentoffastinghyperglycemia,attheexpenseofhigherbodyweightandhypoglycemic
episodes. However, insulin therapy has to be combined with treatment of both peripheral and
liver insulin resistance to normalize blood glucose, and in this case, the insulin regimen is less
important.
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O
nlyafewlong-termstudieshavefo-
cusedondifferentinsulintreatment
modalities and the blinded combi-
nation with different oral antidiabetic
drugs. Theoretically, the best antiglyce-
mic treatment is to aim at restoring the
main pathophysiological defects in type 2
diabetes: decreased ﬁrst-phase insulin se-
cretion, peripheral insulin resistance, and
elevated hepatic gluconeogenesis. These
defects may theoretically be partly cor-
rected pharmacologically by a rapid-
acting insulin analog before meals,
mimicking the lacking postprandial insu-
lin peak; by an insulin sensitizer improv-
ing peripheral insulin action; and by
metformin reducing hepatic glucose pro-
duction (1).
The South Danish Diabetes Study is
aninvestigator-driven2-yearrandomized
controlled clinical trial testing the follow-
ing hypotheses: 1) the more physiological
insulin proﬁle obtained with insulin as-
part treatment at meals (without long-
acting insulin at night) is more effective
than the conventional use of NPH insulin
givenoncedailyatbedtime;2)additionof
metformin or rosiglitazone to insulin
treatment will further improve the glu-
cose control; and 3) combination of insu-
lin, metformin, and rosiglitazone (triple
therapy) will result in the most optimal
glycemic control.
RESEARCH DESIGN AND
METHODS
Subjects
Patients aged 30–70 years with type 2 di-
abetes were included at eight hospital
centers in the southern region of Den-
mark. Eligible patients had the following
characteristics: BMI 25 kg/m
2 and fast-
ingplasmaC-peptide300pmol/l,treat-
ment for at least 3 months with stable
doses of oral antidiabetic medications
and/orinsulin,andA1C7.0%.Priorin-
sulin treatment could be any insulin reg-
imen,butmostsubjectsweretreatedwith
long-actinginsulin.Theexclusioncriteria
were congestive heart failure, impaired
renal function, and known intolerance to
metformin or rosiglitazone and/or treat-
ment with glitazones 30 days before
randomization.
Study design
A total of 450 subjects were included. Af-
tera4-weekrun-inperiod,all371eligible
patients were randomized to one of eight
treatment groups in a factorial design
with NPH insulin versus insulin aspart,
metformin versus placebo, and rosiglita-
zone versus placebo (Fig. 1). After a
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were followed every 3 months for 2 years.
Intervention
All prior antidiabetic treatments were
stopped. Patients allocated to NPH insu-
lin at bedtime measured fasting blood
glucose (FBG) every day and received a
starting dose of 12 IU. Patients already on
insulin received 50% of their prior total
daily dose. In a treat-to-target algorithm,
insulin dose was increased by 2 IU if FBG
was 5.6 mmol/l, 4 IU if FBG was 8.0
mmol/l, and 6 IU if FBG was 12.0
mmol/l on 3 consecutive days until FBG
was 5.5 mmol/l and A1C was 6.5%,
provided no unacceptable hypoglycemic
episodes.
Patients allocated to insulin aspart
measured postprandial blood glucose
three times daily 90 min after each main
meal and received a starting dose of 4 IU
just before each main meal. Patients al-
ready on insulin received 50% of their
prior total daily dose divided into three
doses.Inatreat-to-targetalgorithm,insu-
lin dose at each meal was increased by 1
IU if postprandial blood glucose was
7.5 mmol/l, 2 IU if postprandial blood
glucose was 9.0 mmol/l, 3 IU if post-
prandial blood glucose was 11.0
mmol/l on 3 consecutive days until post-
prandial blood glucose was 7.5 mmol/l
and A1C was 6.5%, provided no limit-
ing hypoglycemic episodes.
After a 3-month intensive insulin ti-
trationperiod,patientswereinstructedto
continue using the algorithm, but daily
blood glucose monitoring was not re-
quested if the treatment goals were
achieved.
Metformin or placebo was given from
the start of the study as one tablet of 500
mg twice daily during the ﬁrst 4 weeks
succeeded by two tablets twice daily, and
rosiglitazone or placebo was given as one
tablet of 4 mg once daily in the ﬁrst 8
weeks succeeded by one tablet twice
daily.
An increase of A1C by 2.0% (abso-
lute) or A1C exceeding 12.0% (absolute),
measured twice over a 6-month period,
were considered treatment failures.
Biochemical and clinical
measurements
A1C was measured every 3 months. Pa-
tients monitored capillary blood glucose
daily (One Touch Ultra, LifeScan) and
performed two eight-point 24-h glucose
proﬁles before each visit.
Safety assessments
Any adverse event was recorded. Hypo-
glycemic episodes were registered by the
patients every day in a diary and were de-
ﬁned as either mild (blood glucose 2.8
mmol/l and symptoms consistent with
hypoglycemia) or moderate (blood glu-
cose 2.8 mmol/l with or without symp-
toms). Serious hypoglycemia was deﬁned
as any hypoglycemic episode requiring
assistance.
Figure 1—Enrollment and outcomes. The number of participants enrolled in the study is shown. The intention-to-treat (ITT) population included
369 patients, since 2 were withdrawn before ﬁrst efﬁcacy evaluation. The per-protocol population included 251 patients. asp, aspart.
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The protocol was in accordance with the
Declaration of Helsinki and approved by
theregionalcommitteeonBiomedicalRe-
search Ethics (M-2417-02). GCP moni-
toring was performed by the local GCP
unit and a contract company. Statistical
analysis was performed by an indepen-
dent statistician. The statistical analysis
plan was completed before the database
was locked and unblinded. Safety data
were reviewed unblinded during the
studybyanindependentacademicdiabe-
tologist. The randomization code was de-
veloped by an independent statistician
using a computer random number gener-
atortoselectrandomblocksofeight.Ran-
domization to insulin type was open,
whereas allocation to other treatments
was double-blinded.
Sample size
The primary outcome variable was A1C.
Assuming a minimal relevant difference
betweenthetwoinsulintreatmentarmsof
0.4% and a standard deviation of 1.15, a
total of 176 in each of the pooled insulin
treatment groups were calculated as nec-
essary to provide the study with 90%
power to detect a difference of this mag-
nitude (P  0.05). Assuming a dropout
rateof10%,atotalofaround400subjects
were planned to be included.
Statistical analysis
The factorial design of the study allowed
us to compare the effect of each compo-
nent in the antidiabetic treatment evalu-
ated but not to compare every eight
treatment groups with each other. In ac-
cordance with the hypothesis, we com-
pared insulin aspart with NPH insulin,
determined the effect of adding met-
formin and/or rosiglitazone to insulin
treatment, and paid special attention to
the effect of triple therapy (insulin plus
metformin plus rosiglitazone). All data
are presented as means  SD or SEM.
Statisticalanalysiswasonanintention-to-
treat basis and last observation carried
forward. A per-protocol analysis for the
primary end point was also performed.
The efﬁcacy analysis (A1C) was per-
formed by ANCOVA on changes from
baseline to the mean of A1C for 12–24
months (inclusive) with the three treat-
mentsandcenterasﬁxedmaineffectsand
baseline A1C value as a covariate. The pa-
tient was a random effect in the model.
First-order interactions and each of the
followingbaselinecovariateswerealsoin-
cluded as ﬁxed effects in the statistical
model: fasting plasma C-peptide, interac-
tion between fasting plasma C-peptide
and treatment, and previous insulin use.
Treatment differences in the number of
patients with A1C 7.0% were tested us-
ing logistic linear regression, with the
threetreatmentsandtheirinteractionsin-
cluded in the model. Plasma glucose pro-
ﬁles were analyzed by a repeated-
measures ANOVA, performed after
logarithmic transformation. Hypoglyce-
mic episodes were analyzed using a gen-
eralized linear model based on the
negative binomial distribution. The num-
ber of patients experiencing at least one
hypoglycemic episode was compared
with the groups using the Fisher exact
test.
RESULTS
Patient characteristics
There were no clinically important differ-
ences in baseline demographic and clini-
cal characteristics between treatment
groups in the study population (Table 1).
Glycemic control
The overall difference between the reduc-
tion in A1C between the aspart and NPH
groups (n  175 vs. 182) was 0.41 
0.10% (P  0.001) (i.e., insulin aspart
was associated with a larger reduction in
A1C than observed with NPH insulin).
Moreover, in all patients, metformin ver-
sus placebo treatment (n  179 vs. 178)
was associated with a decrease in A1C of
0.60  0.10% (P  0.001) and rosigli-
tazoneversusplacebotreatment(n179
vs. 178) with a decrease of 0.55 
0.10% (P  0.001). When only the per-
protocol population was examined, simi-
lar results were observed.
As illustrated in Fig. 2 and Table 2,
A1C decreased in all eight study groups
but most during addition of oral antidia-
betic agents to insulin. There was no dif-
ference between the two triple therapy
groups (aspart versus NPH plus met-
forminandrosiglitazone)(P0.15).Tri-
ple therapy, with any insulin, resulted in
the greatest reduction in A1C compared
with any insulin plus placebo (1.14 
0.13%, P  0.001), any insulin plus ros-
iglitazone (0.50  0.14%, P  0.001),
and any insulin plus metformin
(0.45  0.14%, P  0.001).
The percentages of patients reaching
the A1C target of 7.0% in all patients
wereasfollows:aspartversusNPH,48vs.
42% (P  0.25); metformin versus pla-
cebo, 56 vs. 34% (P  0.001); and ros-
iglitazone versus placebo, 56 vs. 34%
(P  0.002). The percentages reaching
the same goal in the two triple therapy
groups, aspart versus NPH, were 64 ver-
sus 67% (P  0.15).
Self-monitored plasma glucose pro-
ﬁlesweresigniﬁcantlylowerusinginsulin
aspart versus NPH insulin (P  0.005),
metformin versus placebo (P  0.001),
and rosiglitazone versus placebo (P 
0.001) (supplementary Fig. 1, available
in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc10-
0531/DC1).
Insulin dose
Insulin dose was highest in the groups
treatedbyinsulinalone,whereasaddition
of either metformin or rosiglitazone re-
sulted in a decrease in total daily insulin
dose and addition of both metformin and
rosiglitazone resulted in the lowest insu-
lin dose (Table 2).
Hypoglycemia
Overall, more patients using insulin as-
part reported at least one hypoglycemic
episodecomparedwiththepatientsusing
NPH insulin (160 vs. 137, P  0.005),
with no difference between the met-
formin and placebo groups (143 vs. 154,
NS) or between the rosiglitazone and pla-
cebo groups (150 vs. 147, NS).
During the last year of intervention,
treatment with insulin aspart was associ-
ated with more total daytime hypoglyce-
micepisodescomparedwithNPHinsulin
(6.7  9.9 vs. 1.9  5.7, P  0.001).
However, the total number of nocturnal
hypoglycemic episodes was higher in the
NPH insulin group than in the aspart
group (3.0  6.3 vs. 0.5  2.1, P 
0.001).Duringtheentireinterventionpe-
riod, eight patients in the NPH insulin
group experienced eight episodes of se-
vere hypoglycemia and 11 patients in the
aspart group experienced 13 episodes.
Body weight
Body weight increased in all treatment
groups (Table 2). Overall, insulin aspart
was associated with an increase in body
weight of 1.6  0.6 kg (P  0.009) com-
pared with NPH insulin, rosiglitazone
with an increase of 2.3  0.6 kg (P 
0.001) compared with non-rosiglitazone
treatment,andmetforminwithadecrease
in body weight of 2.8  0.6 kg (P 
0.001) compared with non-metformin
treatment.
Gram and Associates
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When the NPH and insulin aspart groups
were compared, statistically signiﬁcant
more adverse events were found in the
insulin aspart group (861 vs. 723) (P 
0.003). There was no statistically signiﬁ-
cant differences between speciﬁc adverse
events between the two groups and no
difference in number of serious adverse
events was found (51 vs. 56) or death (4
vs. 0, Fig. 1). No difference in adverse
events, either in adverse event or in seri-
ous adverse event was found comparing
the metformin and placebo group (seri-
ous adverse event: 53 vs. 54) or the ros-
iglitazone and placebo group (serious
adverse event: 54 vs. 56). (The details of
the speciﬁc adverse events can be found
in supplementary Table 1).
CONCLUSIONS
Effect of insulin treatment on blood
glucose control
The study provides evidence that mono-
therapy with NPH insulin at bedtime is
not an optimal way of treating hypergly-
cemia in type 2 diabetes, although this
treatment has been recommended until
recently (2,3). It could be argued that a
long-acting insulin analog would have
performed better, but in the LANMET
treat-to-target trial comparing NPH insu-
lin and insulin glargine (4), the two insu-
lin treatments combined with metformin
gave identical A1C values.
Treatment with insulin aspart re-
sulted in better blood glucose control
thanNPHinsulin,eventhoughaspartwas
not combined with any basal insulin. The
difference between aspart and NPH treat-
ment on A1C disappeared when com-
bined with metformin or both metformin
and rosiglitazone. The beneﬁt of prandial
insulin treatment was also found during
the ﬁrst year of the 4T study (5) but dis-
appeared in the 2-year follow-up (6)
whenbasal-bolusinsulintreatmentswere
combined.
Recently, another study showed a
nonsigniﬁcant difference in favor of insu-
lin lispro compared with insulin glargine
of 0.2% in A1C (7), which is supported
by an older study also comparing insulin
lisprowithinsulinglargineandshowinga
signiﬁcant reduction in A1C of 0.8% in
the prandial insulin lispro group (8).
It has been shown that postprandial
hyperglycemia is an important determi-
nant for the level of A1C, especially the
closertheA1Cistothetreatmentgoal(9).
This result supports the fact that treat-
T
a
b
l
e
1
—
B
a
s
e
l
i
n
e
c
l
i
n
i
c
a
l
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
t
h
e
s
t
u
d
y
p
o
p
u
l
a
t
i
o
n
N
P
H

p
l
a
c
e
b
o
N
P
H

m
e
t
f
o
r
m
i
n
N
P
H

r
o
s
i
g
l
i
t
a
z
o
n
e
N
P
H

b
o
t
h
N
P
H
t
o
t
a
l
A
S
P

p
l
a
c
e
b
o
A
S
P

m
e
t
f
o
r
m
i
n
A
S
P

r
o
s
i
g
l
i
t
a
z
o
n
e
A
S
P

b
o
t
h
A
S
P
t
o
t
a
l
n
4
6
4
5
4
6
4
6
1
8
3
4
8
4
5
4
7
4
8
1
8
8
S
e
x
(
F
/
M
)
1
3
/
3
3
1
9
/
2
6
1
8
/
2
8
1
6
/
3
0
6
6
/
1
1
7
2
5
/
2
3
1
7
/
2
8
2
0
/
2
7
1
3
/
3
4
7
6
/
1
1
2
A
g
e
(
y
e
a
r
s
)
5
5
.
8

7
.
7
5
5
.
4

8
.
5
5
7
.
3

8
.
9
5
7
.
3

8
.
2
5
6
.
5

8
.
3
5
7
.
1

8
.
5
5
6
.
1

8
.
2
5
6
.
1

8
.
3
5
5
.
3

9
.
1
5
6
.
2

8
.
5
D
i
a
b
e
t
e
s
d
u
r
a
t
i
o
n
(
y
e
a
r
s
)
7
.
3

4
.
3
8
.
2

4
.
0
9
.
2

6
.
9
8
.
1

5
.
3
8
.
2

5
.
2
9
.
1

5
.
5
8
.
7

4
.
5
9
.
4

6
.
3
9
.
0

5
.
8
9
.
1

5
.
5
B
o
d
y
w
e
i
g
h
t
(
k
g
)
1
0
0
.
2

1
9
.
8
1
0
5
.
1

1
7
.
7
1
0
0
.
9

1
6
.
5
1
0
1
.
1

1
9
.
3
1
0
2
.
1

1
8
.
3
9
8
.
3

1
6
.
6
1
0
0
.
5

1
7
.
9
9
5
.
6

1
4
.
6
9
9
.
1

1
6
.
6
9
8
.
3

1
6
.
4
B
M
I
(
k
g
/
m
2
)
3
4
.
0

6
.
0
3
5
.
7

6
.
4
3
4
.
0

5
.
7
3
4
.
4

7
.
0
3
4
.
5

6
.
3
3
3
.
7

5
.
0
3
3
.
7

6
.
1
3
2
.
7

4
.
7
3
2
.
9

4
.
4
3
3
.
2

5
.
0
A
1
C
(
%
)
8
.
7

1
.
3
8
.
9

1
.
2
8
.
7

1
.
2
8
.
5

1
.
1
8
.
7

1
.
3
8
.
5

1
.
2
8
.
5

1
.
2
8
.
3

1
.
0
8
.
5

1
.
2
8
.
5

1
.
1
F
P
G
(
m
m
o
l
/
l
)
1
1
.
2

2
.
6
1
1
.
3

2
.
8
1
0
.
5

2
.
4
1
0
.
2

2
.
6
1
0
.
8

2
.
6
1
0
.
7

2
.
5
1
0
.
0

2
.
3
9
.
9

2
.
1
1
0
.
3

2
.
6
1
0
.
2

2
.
4
F
a
s
t
i
n
g
C
-
p
e
p
t
i
d
e
c
o
n
c
e
n
t
r
a
t
i
o
n
(
p
m
o
l
/
l
)
1
,
0
6
3

4
9
5
1
,
1
1
5

5
0
5
1
,
0
2
6

5
5
4
1
,
0
9
9

5
4
8
1
,
0
7
6

5
2
3
1
,
0
7
0

5
2
8
9
6
7

4
6
0
9
7
5

4
4
0
1
,
0
0
0

4
6
7
1
,
0
0
3

4
7
4
T
r
e
a
t
m
e
n
t
a
t
i
n
c
l
u
s
i
o
n
*
M
e
t
f
o
r
m
i
n
(
%
)
7
8
8
4
7
0
6
7
7
5
7
1
6
9
7
0
6
3
6
8
S
u
l
f
o
n
y
l
u
r
e
a
(
%
)
6
5
5
8
4
6
5
6
5
6
4
8
2
9
5
1
5
2
4
5
I
n
s
u
l
i
n
(
%
)
2
9
3
1
4
6
3
0
3
4
4
8
5
3
5
1
4
2
4
8
D
a
t
a
a
r
e
m
e
a
n
s

S
D
u
n
l
e
s
s
o
t
h
e
r
w
i
s
e
s
t
a
t
e
d
.
*
N
o
p
a
t
i
e
n
t
s
r
e
c
e
i
v
e
d
g
l
i
t
a
z
o
n
e
o
r
D
D
P
-
4
i
n
h
i
b
i
t
o
r
t
r
e
a
t
m
e
n
t
b
e
f
o
r
e
t
h
e
s
t
u
d
y
.
A
S
P
,
i
n
s
u
l
i
n
a
s
p
a
r
t
;
b
o
t
h
,
m
e
t
f
o
r
m
i
n

r
o
s
i
g
l
i
t
a
z
o
n
e
.
The South Danish Diabetes Study
30 DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 care.diabetesjournals.orgment aimed at replacing ﬁrst-phase insu-
lin secretion is important. Furthermore,
anadvantageofthesolelyprandialinsulin
regimens is that, during the night, pa-
tientsareonlycoveredbyendogenousin-
sulin production and therefore do not
develop nocturnal hypoglycemia (10).
Effect of treatment with oral
hypoglycemic agents on blood
glucose control
Both metformin and rosiglitazone as add-
ons to insulin treatment improved the
metabolic control signiﬁcantly and low-
ered the insulin dose, indicating that it is
important not only to give insulin, but
also to improve insulin action in periph-
eral tissues and in the liver. Several previ-
ous studies have addressed the issue of
combining insulin and metformin treat-
mentandhaveindicatedaclearadvantage
of doing so (11–15).
Most studies on combination treat-
ment with glitazone and insulin have
found an improvement in glycemic con-
trol compared with insulin given in
monotherapy (15–19). Moreover, glita-
zones also have an insulin-sparing effect
(15–18). However, the combination
treatmentisassociatedwithanincreasein
body weight (15–19).
Effect of triple therapy treatment on
blood glucose control
The most optimal treatment with respect
toglycemiccontrolinourstudywastriple
therapy using insulin, rosiglitazone, and
metformin. Around 66% of our patients
treated with triple therapy reached the
A1C target of 7.0%. A similar high pro-
portion of responders have only rarely
been achieved in other randomized trials
of insulin treatment in type 2 diabetes be-
sides in the advanced insulin regimens
groups in the 4T trial (6). The same com-
bination therapy has been investigated in
a few short-term studies previously
(10,20–23).
The triple concept gave identical re-
sults no matter what insulin regimen was
used. The reason for this seems to be that
insulinaspartonlyreplacesﬁrst-phasein-
sulin secretion and NPH insulin only
basal insulin secretion, thus not covering
the full 24-h period adequately. Based on
the 4T follow-up study (6), it may be
speculated that the combined effect of
prandial aspart and basal NPH insulin is
the best treatment.
Hypoglycemia
The overall numbers of clinically relevant
hypoglycemic episodes were low, being
comparable to the numbers reported in
the 4T trial (5). Despite the surplus of hy-
poglycemic episodes in the insulin aspart
group, the majority of episodes were dur-
ing the daytime, which may be more ac-
ceptable than nocturnal episodes seen
more often in the NPH insulin group.
Moreover, it can be speculated if the mea-
surements of postprandial glucose con-
centration thrice daily in the aspart
groups made this group more prone to
Figure 2—Mean  SE observed A1C values during the 2-year intervention period in patients randomized to treatment with either NPH insulin
(blacksymbols)orinsulinaspart(opensymbols)incombinationwithplacebo(A,P0.001),metformin(B,P0.15),rosiglitazone(C,P0.02),
or metformin and rosiglitazone (D, P  0.15).
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the day.
Body weight
It is well known that improvement in
blood glucose control often increases
body weight. Insulin treatment in combi-
nation with glitazones may result in more
weight gain than other treatments (24).
However, interestingly, if we compared
the weight gain using triple therapy with
insulin, metformin, and rosiglitazone, it
was comparable to that observed with in-
sulin treatment alone, as also seen in the
4T study (5).
Adverse effects
There is no clear explanation for the in-
creased number of adverse events found
intheaspart-treatedgroups.Itwasseenin
all system organ classes but not in the
number of serious adverse events or
death. All adverse events were noted by
the patients in their diabetes diary, and it
maybespeculatedifthethrice-dailymea-
surement and notation of blood glucose
made them more prone to report adverse
events than the NPH group only measur-
ing FBG.
The recently published ACCORD,
ADVANCE, and VADT studies show no
beneﬁt in relation to reduction in cardio-
vascular disease risk with improvements
in glycemic control. It is important to re-
alize that our study was not a study de-
signed to address this issue. Moreover, it
seems from the recent follow-up study of
the UK Prospective Diabetes Study (25)
that normalization of glycemic control
should be obtained when the diagnosis of
type 2 diabetes is made and further that
thebeneﬁtsofimprovedglycemiccontrol
are maintained many years after the study
intervention (25).
In conclusion, treatment of postpran-
dial hyperglycemia with insulin aspart re-
sults in lower A1C than treatment of
fasting hyperglycemia with NPH insulin,
but with more side effects. For optimal
treatment, insulin must be combined
with treatment of both peripheral and
liver insulin resistance, and, in this case,
the choice of insulin regimen is less
important.
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